ulcerative colitis
| 5 min read
Jeremy Gale leads Pfizer’s inflammation & immunology research program to develop new therapies for moderate to severe inflammatory bowel disease.
Available on Demand
Spatial biology platforms shed light on the cellular and molecular players underlying ulcerative colitis and Crohn’s disease.
Page 1 of 1 - 2 Total Items
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
The unsung tools behind analytical testing success
Learn how fundamental laboratory tools like pipettes and balances support analytical precision.
Improving ALS research with pluripotent stem cell-derived models
Discover new advancements in modeling amyotrophic lateral sclerosis.
Automating 3D cell selection
Discover precise automated tools for organoid and spheroid handling.
